Exagen Inc Stock Today

XGN Stock  USD 5.00  0.05  1.01%   

Performance

12 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Over 70

 
High
 
Low
Quite High
Exagen is selling at 5.00 as of the 24th of December 2024; that is 1.01 percent increase since the beginning of the trading day. The stock's open price was 4.95. Exagen has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 27th of June 2024 and ending today, the 24th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of September 2019
Category
Healthcare
Classification
Health Care
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. The company has 17.64 M outstanding shares of which 57.22 K shares are at this time shorted by investors with about 3.12 days to cover. More on Exagen Inc

Moving together with Exagen Stock

  0.77DMAC DiaMedica TherapeuticsPairCorr

Moving against Exagen Stock

  0.92VIGL Vigil NeurosciencePairCorr
  0.89DRRX DurectPairCorr
  0.89DTIL Precision BioSciencesPairCorr
  0.87VALN Valneva SE ADRPairCorr
  0.73DNLI Denali TherapeuticsPairCorr
  0.73DNTH Dianthus TherapeuticsPairCorr

Exagen Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President, CEOJohn Aballi
Thematic IdeaHealthcare (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.540.9228
Way Down
Slightly volatile
Total Current Liabilities9.7 M11.9 M
Significantly Down
Very volatile
Non Current Liabilities Total20.3 M22.3 M
Significantly Down
Slightly volatile
Total Assets54.2 M56.9 M
Notably Down
Slightly volatile
Total Current Assets44 M47.8 M
Significantly Down
Slightly volatile
Debt Levels
Exagen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Exagen's financial leverage. It provides some insight into what part of Exagen's total assets is financed by creditors.
Liquidity
Exagen Inc has 23.72 M in debt with debt to equity (D/E) ratio of 0.55, which is OK given its current industry classification. Exagen Inc has a current ratio of 9.11, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Exagen to invest in growth at high rates of return.

Depreciation

2.28 Million
Exagen Inc (XGN) is traded on NASDAQ Exchange in USA. It is located in 1261 Liberty Way, Vista, CA, United States, 92081 and employs 174 people. Exagen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 87.3 M. Exagen Inc runs under Biotechnology sector within Health Care industry. The entity has 17.64 M outstanding shares of which 57.22 K shares are at this time shorted by investors with about 3.12 days to cover. Exagen Inc has about 76.39 M in cash with (14.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7.
Check Exagen Probability Of Bankruptcy
Ownership Allocation
Exagen holds a total of 17.64 Million outstanding shares. Over half of Exagen's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Exagen Ownership Details

Exagen Stock Institutional Holders

InstituionRecorded OnShares
Ubs Group Ag2024-09-30
78.5 K
Palumbo Wealth Management Llc2024-09-30
76.4 K
Penbrook Management Llc2024-09-30
63 K
Nantahala Capital Management, Llc2024-09-30
62.1 K
Blackrock Inc2024-06-30
43.6 K
Creative Planning Inc2024-09-30
35.5 K
Dimensional Fund Advisors, Inc.2024-09-30
29.8 K
State Street Corp2024-09-30
27.7 K
Citadel Advisors Llc2024-09-30
23 K
Rtw Investments, Llc2024-09-30
1.5 M
Cowen And Company, Llc2024-09-30
891.4 K
View Exagen Diagnostics

Exagen Historical Income Statement

At this time, Exagen's Depreciation And Amortization is very stable compared to the past year. As of the 24th of December 2024, Interest Expense is likely to grow to about 2.8 M, while Total Revenue is likely to drop about 32.2 M. View More Fundamentals

Exagen Stock Against Markets

Exagen Corporate Management

Jeffrey BlackChief OfficerProfile
Debra ZackChief OfficerProfile
John WegenerSenior MarketingProfile
Ryan DouglasInvestors OfficerProfile
Mark HazeltineChief OfficerProfile
MingChou LeeChief OfficerProfile

Already Invested in Exagen Inc?

The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
3.163
Quarterly Revenue Growth
0.066
Return On Assets
(0.17)
Return On Equity
(0.70)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.